Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Antibe Therapeutics Inc. announces an upcoming poster presentation at the American Academy of Pain Medicine’s Annual Meeting, showcasing their lead drug, otenaproxesul, and its potential as a non-abusable and innovative anti-inflammatory/analgesic alternative to opioids. The presentation by the company’s Chief Medical Officer will highlight the drug’s pharmacokinetics, safety, and role in addressing the urgent need for new pain treatments. Antibe is focused on developing therapies that mitigate the side effects associated with current NSAIDs and provide safer options for pain and inflammation management.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.
